AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01527305
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
Trial: NCT02482428
Drug: Aldara
RxNorm normalized name: Aldara
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Applied 3 times a week for 16 weeks
Trial: NCT00945347
Drug: Miglustat
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nasal instillation of miglustat
Trial: NCT02407080
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
Trial: NCT02744495
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Trial: NCT02744495
Drug: Droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
Trial: NCT03347526
Drug: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injectable + oral solution
Trial: NCT03347526
Drug: Vigabatrin
RxNorm normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01097265
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01934712
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose injected subcutaneously (s.c, under the skin)
Trial: NCT01934712
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose injected subcutaneously (s.c, under the skin)
Trial: NCT00443872
Drug: orally disintegrating selegiline (Zelapar)
RxNorm normalized name: selegiline Disintegrating Oral Tablet
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
Trial: NCT04410562
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
Trial: NCT01343186
Drug: Peginterferon alfa
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s,c, 45mcg of Ypeginterferon alfa-2a
Trial: NCT01343186
Drug: Peginterferon alfa 2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Trial: NCT01343186
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Trial: NCT01343186
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
Trial: NCT02912494
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02994082
Drug: Nicotine replacement therapy - transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Trial: NCT02994082
Drug: Nicotine replacement therapy - nicotine lozenge
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Trial: NCT02994082
Drug: Nicotine replacement therapy - nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Trial: NCT02994082
Drug: Bupropion sustained release
RxNorm normalized name: bupropion Extended Release Oral Tablet
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Trial: NCT02994082
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications.
Trial: NCT02994082
Drug: Combination nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
Trial: NCT02994082
Drug: Combination nicotine replacement therapy + bupropion
RxNorm normalized name: nicotinic acid, combinations
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
Trial: NCT01109121
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 400 mg, QD
Trial: NCT01157572
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
Trial: NCT00104416
Drug: lamotrigine (LAMICTAL) extended-release
RxNorm normalized name: lamotrigine Extended Release Oral Tablet
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary experimental dosage form
Trial: NCT01450696
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
Trial: NCT01450696
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Trial: NCT00515606
Drug: helium:oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03668496
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
Trial: NCT00073736
Drug: MB07133 300mg/m2/day
DrugBank: MB07133 (DB17139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous infusion in 28-day cycles
Trial: NCT00073736
Drug: MB07133 600 mg/m2/day
DrugBank: MB07133 (DB17139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous infusion in 28-day cycles
Trial: NCT00073736
Drug: MB07133 1200 mg/m2/day
DrugBank: MB07133 (DB17139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous infusion in 28-day cycles
Trial: NCT00073736
Drug: MB07133 1800 mg/m2/day
DrugBank: MB07133 (DB17139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous infusion in 28-day cycles
Trial: NCT00073736
Drug: MB07133 2400 mg/m2/day
DrugBank: MB07133 (DB17139)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day continuous infusion in 28-day cycles
Trial: NCT00883168
Drug: azelastineHcl
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: azelastine hydrochloride 548 mg
Trial: NCT00883168
Drug: fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fluticasone propionate 200 mcg
Trial: NCT00883168
Drug: azelastine Hcl/fluticasone propionate
RxNorm normalized name: azelastine HCl/fluticasone propionate 137 mcg-50 mcg/spray NASAL AEROSOL, SPRAY WITH PUMP (GRAM)
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
Trial: NCT00610857
Drug: Anti-CTLA4 monoclonal antibody and HDI
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
Trial: NCT04296305
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV after
Trial: NCT02460367
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02460367
Drug: Indoximod
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03629223
Drug: Tepotinib TF2
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
Trial: NCT03629223
Drug: Tepotinib TF3
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
Trial: NCT02853552
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800mcg misoprostol taken sublingually
Trial: NCT04475523
Drug: CI-8993
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
Trial: NCT00100074
Drug: Lobeline
RxNorm normalized name: lobeline
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00586716
Drug: intravenous immune globulin
RxNorm normalized name: Intravenous immune globulin (human)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
Trial: NCT03115827
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
Trial: NCT03115827
Drug: Carbidopa
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa 200mg twice a day
Trial: NCT01312493
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
Trial: NCT00203866
Drug: G250 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00203866
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02728648
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pain Management
Trial: NCT03668470
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dulaglutide 1.5mg : One injection per week during 24 weeks
Trial: NCT00964002
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03773536
Drug: Artesunate-amodiaquine given with single low dose primaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
Trial: NCT01584791
Drug: clopidogrel napadisilate + aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel napadisilate 75mg + aspirin 100mg
Trial: NCT01584791
Drug: clopidogrel bisulfate + aspirin
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel bisulfate 75mg + aspirin 100mg
Trial: NCT02771574
Drug: Lyo avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
Trial: NCT02771574
Drug: Liq avexitide
RxNorm normalized name: Avexitide
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
Trial: NCT01920919
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00323960
Drug: 3 MPDN pulse + PDN + CSA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
Trial: NCT00323960
Drug: 3 MPDN pulse + PDN + MTX
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
Trial: NCT01780337
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal dose of 20 IU oxytocin
Trial: NCT01127464
Drug: DCVax-001
RxNorm normalized name: DCVax-L
DrugBank: DCVax-L (DB17580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
Trial: NCT01127464
Drug: Poly-ICLC
RxNorm normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
Trial: NCT00151684
Drug: Diazoxide
RxNorm normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00479817
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg
Trial: NCT00479817
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg
Trial: NCT00479817
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
Trial: NCT01200654
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
Trial: NCT02866006
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02693080
Drug: Isovue-200
RxNorm normalized name: Isovue-200
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Contrast agent
Trial: NCT00366600
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272
Trial: NCT00543933
Drug: iNO administered
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iNO at 40 ppm through a non-rebreather mask for 5 minutes
Trial: NCT02953379
Drug: EMS Mometasone gel
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient should administer 2 spray in each nostril, once daily.
Trial: NCT02953379
Drug: Mometasone spray nasal
RxNorm normalized name: mometasone Metered Dose Nasal Spray
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient should administer 2 spray in each nostril, once daily.
Trial: NCT00613327
Drug: Oxybutynin chloride OROS
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
Trial: NCT04679506
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
Trial: NCT03160248
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
Trial: NCT00118248
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00140049
Drug: Xalacom
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00140049
Drug: Cosopt
RxNorm normalized name: Cosopt
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00700882
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Trial: NCT04166578
Drug: lignocaine
RxNorm normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
Trial: NCT01145001
Drug: Nicotine Transdermal Patch
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14mg ir 21mg doses based on weight and #cigs/day
Trial: NCT00361231
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Trial: NCT00361231
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.